Descartes-08

clinical study of an investigational cell therapy for treatment of generalized Myasthenia Gravis (MG)

What is Myasthenia Gravis?

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness and fatigue of muscles. The clinical course of MG is variable but usually progressive. Symptoms typically emerge in the eyes (e.g., drooping eyes, double vision, blurred vision) (ocular MG) or progress to involve the face, throat and limbs (generalized MG).

About Descartes-08

Descartes-08 is a T-cell therapy that is custom-made from a patient’s own blood. The cells are engineered with an mRNA to redirect them to find and kill antibody-producing plasma cells. It is hoped that these T-cells, when administered back to the patient, will find and kill the aberrant plasma cells that produce the pathogenic antibodies in MG.

Who can participate in the study?

You may be eligible to participate in this clinical study if you are over the age of 18 and:

  • You have Generalized Myasthenia Gravis
  • Concomitant immunosuppressive drugs are deemed necessary

Only a member of our study team can determine your final eligibility. To learn more, please find your local study center from the list below and schedule a screening visit.

What can participants expect?

Descartes-08 is an investigational drug designed to study the safety and possible benefits in patients with MG.

Patients will undergo leukapheresis, where T cells will be collected from your blood and sent to a lab to be turned into Descartes-08 cells. Participation will last approximately 12 months and require several visits to the study center.

Find a study center near you

To see if Descartes-08 is right for you, please find your local study center from the list below, then contact a member of our study team to schedule your screening visit.

For additional study information, please visit: https://clinicaltrials.gov/ct2/show/NCT04146051

University of California Irvine

Principal investigator: Tahseen Mozaffar, MD
Clinical Research Coordinator : Julia Fong

200 S. Manchester Orange, CA 92868
E-mail: juliakf@hs.uci.edu
Phone number: (714)-456-2864

Barrow Neurological Institute

Principal Investigator: Shafeeq Ladha, MD
Clinical Research Coordinator: Nicole Turcotte
Dignity Health St. Joseph’s Hospital and Medical Center
240 W. Thomas Road, Suite 400, Phoenix, AZ, 85013
E-mail: nicole.turcotte@dignityhealth.org
Phone number: (602)-406-4775

Oregon Health & Science University

Principal Investigator: Nizar Chahin, MD
Clinical Research Coordinator: Diana Dimitrova
3303 S Bond Ave, Portland, OR 97239
E-mail: dimitrov@ohsu.edu
Phone number: (503)-494-0744

University of North Carolina

Principal Investigator: Chip Howard, MD
Clinical Research Coordinator:  Manisha Chopra
170 Manning Drive, Campus Box 7025
Chapel Hill, NC 27599-7025
E-mail:  chopram@neurology.unc.edu
Phone number: (919)-843-7857

The Research Center of Southern California

Principal Investigator: Gregory Sahagian, MD

Research Department Manager: April Tenorio, CCRC

The Research Center of Southern California

A Division of North County Neurology Associates

6010 Hidden Valley Road, Suite #200

Carlsbad, CA 92011

Phone number: 760-732-0557 x 2135 p

Email: tenorioa@neurocenter.com

Neurology Associates, P.A.

Principal Investigator: Adam Slansky MD
Research Department Manager: Kelly Holley
331 North Maitland, Ave, Suite A-1
Maitland, Florida 32751
Phone number: 407-646-5996 ext
Emal: neurologyassoc@hotmail.com

SFM Clinical Research, LLC

Principal Investigator: Marc Feinberg MD
Clinical Research Manager: Gabrielle DeMaria, MS
Email: gabrielle@sfmresearch.com
Clinical Research Coordinator: Yousra Erritouni
Email: yousra@sfmresearch.com
SFM Clinical Research, LLC | South Florida Neurology Associates,
P.A. 1601 Clint Moore Rd, Suite 120, Boca Raton, FL 33487

Office – 561.939.0333 | Mobile – 561.419.4303

Frequently asked questions

During a clinical study, a medication is being evaluated to determine whether or not it may help you. If you participate, you may also have the following procedures performed to monitor your health: vital signs, blood work, physical exams, and other types of assessments that are necessary to gather the required information about the study medication. All study volunteers are always closely monitored by clinic staff and the medical team to ensure their safety. 

There will be approximately 18 patients taking part in this study at multiple study centers across the U.S.

Participation in any clinical study is completely voluntary. Your decision to participate – or not participate – in this clinical study will have no effect on the medical care that you receive now or in the future. If you are eligible and choose to participate in the study, you may leave the clinical study at any time, and for any reason.

There are many reasons to participate in clinical research. For starters, it allows participants to play a more proactive role in their own health by receiving a new treatment for an ongoing disease or condition. Participants also play an important part in bringing much-needed drugs to market, benefiting thousands of people who also have the disease or condition.

This study is regulated by the U.S. Food and Drug Administration (FDA) and independent local and central Institutional Review Boards (IRB) to ensure that the study conforms to regulatory standards set forth for U.S. clinical trials. You will have an opportunity to review participation risks in detail prior to deciding to enroll in the study.

The study centers and Cartesian Therapeutics, Inc. are responsible for conducting this clinical trial.

Scroll to Top